27964699|t|A Review of Hypertension Management in Atrial Fibrillation
27964699|a|Atrial fibrillation (AF) is one of the commonest arrhythmias in clinical practice and has major healthcare and economic implications. It is a growing epidemic with prevalence all set to double to 12 million by 2050. After adjusting for other associated conditions, hypertension confers a 1.5- and 1.4-fold risk of developing AF, for men and women respectively. Furthermore, in patients with AF, the presence of hypertension has a cumulative effect on the risk of stroke. Growing evidence suggests reversal or attenuation of various structural and functional changes predisposing to AF with the use of antihypertensive medications. Randomized trials have shown major reduction in the risk of stroke and heart failure with blood pressure reduction. However, such trials are lacking in AF patients specifically. The Joint National Committee-8 guidelines have not addressed the threshold or goal BP for patients with known AF. Furthermore, "J-shaped" or "U-shaped" curves have been noted during hypertension management in patients with AF with published data demonstrating worse outcomes in patients with strict BP control to <110/60 mmhg similar to coronary artery disease. In this review, we outline the available literature on management of hypertension in patients with AF as well as the role of individual anti-hypertensive medications in reducing the incidence of AF Fig. 1.
27964699	12	24	Hypertension	T047	C0020538
27964699	25	35	Management	T058	C0376636
27964699	39	58	Atrial Fibrillation	T047	C0004238
27964699	59	78	Atrial fibrillation	T047	C0004238
27964699	80	82	AF	T047	C0004238
27964699	98	107	commonest	T081	C0205214
27964699	108	119	arrhythmias	T046	C0085611
27964699	123	140	clinical practice	T057	C0205897
27964699	155	165	healthcare	T058	C0086388
27964699	170	178	economic	T169	C0013557
27964699	209	217	epidemic	T067	C0014499
27964699	223	233	prevalence	T081	C0220900
27964699	301	322	associated conditions	T046	C0243082
27964699	324	336	hypertension	T047	C0020538
27964699	365	369	risk	T078	C0035647
27964699	384	386	AF	T047	C0004238
27964699	392	395	men	T098	C0025266
27964699	400	405	women	T098	C0043210
27964699	436	444	patients	T101	C0030705
27964699	450	452	AF	T047	C0004238
27964699	458	466	presence	T033	C0150312
27964699	470	482	hypertension	T047	C0020538
27964699	489	499	cumulative	T080	C1511559
27964699	500	506	effect	T080	C1280500
27964699	514	518	risk	T078	C0035647
27964699	522	528	stroke	T047	C0038454
27964699	538	546	evidence	T078	C3887511
27964699	547	555	suggests	T078	C1705535
27964699	568	579	attenuation	T052	C0599946
27964699	591	601	structural	T082	C0678594
27964699	606	616	functional	T169	C0205245
27964699	617	624	changes	T169	C0392747
27964699	625	637	predisposing	T169	C0231203
27964699	641	643	AF	T047	C0004238
27964699	660	688	antihypertensive medications	T121	C0003364
27964699	690	707	Randomized trials	T062,T170	C0206034
27964699	725	734	reduction	T061	C0441610
27964699	742	746	risk	T078	C0035647
27964699	750	756	stroke	T047	C0038454
27964699	761	774	heart failure	T047	C0018801
27964699	780	794	blood pressure	T040	C0005823
27964699	795	804	reduction	T061	C0441610
27964699	820	826	trials	T062	C0008976
27964699	831	838	lacking	T080	C0332268
27964699	842	844	AF	T047	C0004238
27964699	845	853	patients	T101	C0030705
27964699	872	898	Joint National Committee-8	T058	C0086034
27964699	899	909	guidelines	T170	C0162791
27964699	951	953	BP	T040	C0005823
27964699	958	966	patients	T101	C0030705
27964699	978	980	AF	T047	C0004238
27964699	1050	1062	hypertension	T047	C0020538
27964699	1063	1073	management	T058	C0376636
27964699	1077	1085	patients	T101	C0030705
27964699	1091	1093	AF	T047	C0004238
27964699	1099	1108	published	T057	C0034037
27964699	1109	1113	data	T078	C1511726
27964699	1128	1133	worse	T033	C1457868
27964699	1134	1142	outcomes	T169	C1274040
27964699	1146	1154	patients	T101	C0030705
27964699	1167	1177	BP control	T061	C0419171
27964699	1194	1201	similar	T080	C2348205
27964699	1205	1228	coronary artery disease	T047	C0010068
27964699	1238	1244	review	T170	C0282443
27964699	1271	1281	literature	T170	C0023866
27964699	1285	1295	management	T058	C0376636
27964699	1299	1311	hypertension	T047	C0020538
27964699	1315	1323	patients	T101	C0030705
27964699	1329	1331	AF	T047	C0004238
27964699	1355	1365	individual	T098	C0237401
27964699	1366	1395	anti-hypertensive medications	T121	C0003364
27964699	1399	1407	reducing	T080	C0392756
27964699	1412	1421	incidence	T081	C0021149
27964699	1425	1427	AF	T047	C0004238